Krystal Biotech Inc (KRYS) is a Healthcare · Biotechnology company listed on NASDAQ. Price $336.67 (-0.61%), Market cap $8.61B, P/E ratio 39.12, 52-week low–high $123.36 ~ $316.30.
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular complications of dystrophic epidermolysis bullosa; KB801 for neurotrophic keratitis; KB407, which is in Phase 1 clinical trials for treating cystic fibrosis; KB111 for Hailey-Hailey disease; KB707 for solid tumors; KB304 for dynamic wrinkles; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapse
Financial statements, price targets, institutional (13F) holdings and related news for Krystal Biotech Inc are updated in real time on BlackAll Trade.
Krystal Biotech Inc trades at $336.67 (-0.61%). Real-time quotes and charts are available on BlackAll Trade.
Krystal Biotech Inc has a market cap of about $8.61B. Its P/E ratio is 39.12.
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United S